Atossa Genetics Inc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

ATOS 1.21 -0.01 (-0.82%)
price chart
Atossa Genetics (ATOS) Stock Declines Today on Heavy Trading Volume
"We rate ATOSSA GENETICS INC (ATOS) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the ...
Know before you invest: Atossa Genetics Inc (NASDAQ:ATOS), American ...  Markets Emerging
Atossa Genetics Inc (NASDAQ:ATOS): This Stock May Be Undervalued  USMarketsDaily (blog)
Related articles »  
Why did Atossa Genetics shares jump 35 percent on Wednesday?
Zacks said Atossa's revenues should grow by 230 percent in the next six years and the company should be profitable in 2019.
Atossa up on heavy volume (ATOS)  Seeking Alpha
Pre-Christmas Trading In Atossa Genetics Inc (NASDAQ:ATOS): Stock Up 35%  FinancialsTrend
Related articles »  
Atossa Genetics Inc. Provides Update on Pharmacogenetics Testing Now ...
SEATTLE, WA, Dec 19, 2014 (Marketwired via COMTEX) -- Atossa Genetics Inc. ATOS, +0.00% today announced that its subsidiary, The National Reference Laboratory for Breast Health, Inc. (the NRLBH), a CLIA-certified laboratory located in Seattle, ...
Related articles »  
Atossa Genetics Announces the Publication of: Proliferative Epithelial Disease ...
SEATTLE, WA, Jan 19, 2015 (Marketwired via COMTEX) -- Atossa Genetics Inc. ATOS, -3.24% today announced that a study titled Proliferative Epithelial Disease Identified in Nipple Aspirate Fluid and Risk of Developing Breast Cancer: A Systematic Review ...
Atossa Genetics Inc Analyst Rating Update
As many as 2 brokerage firms have rated Atossa Genetics Inc (NASDAQ:ATOS) at 1. Research Analysts at Zacks have ranked the company at 1, suggesting the traders with a rating of Outperform.
Short Interest in Atossa Genetics Increases By 54.5% (ATOS)  Mideast Time
Atossa Genetics touts 'successful closure of FDA inspections'
Atossa Genetics Inc. said Friday that it has received "successful closure of FDA inspections." The news sent shares of Atossa Genetics (NASDAQ: ATOS), the Seattle maker of a breast health test that's been off the U.S.
Atossa Genetics (ATOS) Reports Closure of FDA Probe  StreetInsider.com (subscription)
Related articles »  
Atossa Genetics gets bad news from FDA, shares dive
In early Wednesday pre-market trading, shares in Atossa Genetics (NASDAQ: ATOS) had fallen more than 50 percent, dropping $1.23 to $1.10.
Atossa Genetics Inc (NASDAQ:ATOS) To Focus On Commercial Launch Of ...  USMarketsDaily
7 Big Slumps: Atossa Genetics (ATOS), Baxano Surgical (BAXS), Chinanet ...  Markets Emerging
Related articles »  
Atossa Genetics Inc (ATOS): An Expanding Distribution Infrastructure Augurs ...
(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.) The shares of Atossa Genetics, Inc. (ATOS) soared 21.0% on September 19th on more than 37-times the normal daily trading volume. At its ...
Atossa Genetics: My Top Biotech Idea For 2013
The name of the company is Atossa Genetics (NASDAQ:ATOS). I am so excited about the prospects of this company that I am naming it my best biotech idea for the year. Atossa Genetics is at the forefront of breakthrough procedures to make breast cancer a ...
Atossa Genetics Inc. Hires Pieter van der Poel as Vice President of European ...
SEATTLE, WA--(Marketwired - Dec 16, 2014) - Atossa Genetics Inc. ( NASDAQ : ATOS) today announced that it has hired Pieter van der Poel as Vice President of European Commercial Operations effective December 15, 2014.
Related articles »